Novo Nordisk | Wegovy shows major CV benefit vs. tirzepatide

$NVO (-1.3%)
$NOVO B (-1.57%)

• Real-world study: 57% lower risk of heart attack, stroke, or death with Wegovy in obese patients w/ CV disease

• Strengthens case for broad adoption in obesity & cardiometabolic care

• Adds fuel to rivalry with Eli Lilly’s $LLY tirzepatide in weight-loss market